An Adaptive Biotechnologies Insider Sold $8.5 Million in Stock After an 85% Run

Harlan Robins, chief scientific officer of Adaptive Biotechnologies, sold 386,240 shares worth $8.5 million on July 2, 2026, under a pre-scheduled Rule 10b5-1 trading plan established in March. Despite the sale, Robins retained over 1 million shares valued at $21.6 million. The transaction appears to be a diversification move rather than a sign of concern, as the company's MRD diagnostics business is accelerating with 35% revenue growth and narrowing losses.